| ［1］ |
Wang Q, Zhu H, Sun X, et al. Loss⁃of⁃function mutations in PLD4 lead to systemic lupus erythematosus［J］. Nature, 2025,647（8089）:498⁃505. DOI: 10.1038/s41586⁃025⁃09513⁃x.
|
| ［2］ |
Tumurkhuu G, Perri G, Moore R, et al. Loss of tripartite motif⁃containing protein 21 and UVB⁃induced systemic inflammation by regulating DNA⁃sensing pathways［J］. Arthritis Rheumatol, 2026,78（1）:172⁃183. DOI: 10.1002/art.43273.
|
| ［3］ |
Zeng Q, Li L, Li X, et al. The m6A demethylase FTO links TLR7 to mitochondrial oxidation driving age⁃associated B cell formation in systemic lupus erythematosus［J］. Sci Transl Med, 2025,17（823）:eadu6015. DOI: 10.1126/scitranslmed.adu6015.
|
| ［4］ |
Yuen E, Fried J, Nguyen SA, et al. Hearing loss in patients with systemic lupus erythematosus: a systematic review and meta⁃analysis［J］. Lupus, 2021,30（6）:937⁃945. DOI: 10.1177/09612 03321997919.
|
| ［5］ |
Zhao Z, Li A, Zhu Y, et al. Blood⁃labyrinth barrier damage mediated by granzymes from cytotoxic lymphocytes results in hearing loss in systemic lupus erythematosus［J］. Proc Natl Acad Sci U S A, 2025,122（33）:e2423240122. DOI: 10.1073/pnas. 2423240122.
|
| ［6］ |
Wang J, Zheng A, Liu N, et al. Integrative spatial multiomics analysis reveals regulatory mechanisms of VCAM1+ proximal tubule cells in lupus nephritis［J］. Ann Rheum Dis, 2025,84（12）:2021⁃2033. DOI: 10.1016/j.ard.2025.08.015.
|
| ［7］ |
Nikolopoulos D, Sentis G, Kitsios I, et al. Enhanced B cell and complement cascade gene signatures in patients with neuropsychiatric systemic lupus erythematosus［J］. Ann Rheum Dis, 2025,84（8）:1342⁃1353. DOI: 10.1016/j.ard.2025.04.006.
|
| ［8］ |
Li T, Lin S, Guan Z, et al. A deep learning system for detecting systemic lupus erythematosus from retinal images［J］. Cell Rep Med, 2025,6（7）:102203. DOI: 10.1016/j.xcrm.2025.102203.
|
| ［9］ |
Zaslavsky ME, Craig E, Michuda JK, et al. Disease diagnostics using machine learning of B cell and T cell receptor sequences［J］. Science, 2025,387（6736）:eadp2407. DOI: 10.1126/science.adp2407.
|
| ［10］ |
Azoulay LD, Kachenoura N, Boussouar S, et al. Diagnostic and prognostic value of quantitative cardiac magnetic resonance imaging biomarkers in systemic lupus erythematosus: a systematic review and meta⁃analysis［J］. Eur Radiol, 2025,35（7）:3858⁃3870. DOI: 10.1007/s00330⁃024⁃11282⁃6.
|
| ［11］ |
国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组, 中华医学会风湿病学分会. 中国系统性红斑狼疮诊疗指南（2025版）［J］. 中华医学杂志, 2025,105（23）:1879⁃1906. DOI: 10.3760/cma.j.cn112137⁃20250228⁃00479.
|
| ［12］ |
Sammaritano LR, Askanase A, Bermas BL, et al. 2025 American College of Rheumatology （ACR） guideline for the treatment of systemic lupus erythematosus［J］. Arthritis Rheumatol, 2026,78（7）:1361⁃1386.
|
| ［13］ |
van Vollenhoven RF, Wang L, Merrill JT, et al. A phase 3 trial of telitacicept for systemic lupus erythematosus［J］. N Engl J Med, 2025,393（15）:1475⁃1485. DOI: 10.1056/NEJMoa2414719.
|
| ［14］ |
Manzi S, Bruce IN, Morand EF, et al. Efficacy and safety of subcutaneous anifrolumab in systemic lupus erythematosus: a randomized, phase 3 study［J］. Arthritis Rheumatol, 2026,78（6）:1258⁃1267. DOI: 10.1002/art.70041.
|
| ［15］ |
Wang Q, Xiao ZX, Zheng X, et al. In vivo CD19 CAR T⁃cell therapy for refractory systemic lupus erythematosus［J］. N Engl J Med, 2025,393（15）:1542⁃1544. DOI: 10.1056/NEJMc2509522.
|
| ［16］ |
Wang X, Zhang Y, Wang H, et al. Allogeneic CD19⁃targeting T cells for treatment⁃refractory systemic lupus erythematosus: a phase 1 trial［J］. Nat Med, 2025,31（11）:3713⁃3724. DOI: 10. 1038/s41591⁃025⁃03899⁃x.
|
| ［17］ |
Feng J, Huo D, Hong R, et al. Co⁃infusion of CD19⁃targeting and BCMA⁃targeting CAR⁃T cells for treatment⁃refractory systemic lupus erythematosus: a phase 1 trial［J］. Nat Med, 2025,31（11）:3725⁃3736. DOI: 10.1038/s41591⁃025⁃03937⁃8.
|
| ［18］ |
Gao J, Li M, Sun M, et al. Efficacy and safety of allogeneic CD19 CAR NK⁃cell therapy in systemic lupus erythematosus: a case series in China［J］. Lancet, 2026,406（10522）:2968⁃2979. DOI: 10.1016/S0140⁃6736（25）01671⁃X.
|
| ［19］ |
Liang Z, Xie H, Mao M, et al. Immune mediated inflammatory disease: T cell engager versus antibody drug conjugate［J］. J Autoimmun, 2025,157:103497. DOI: 10.1016/j.jaut.2025.103497.
|
| ［20］ |
Wu K, DeVita RJ, Pan ZQ. Modulation of Cullin⁃RING E3 ubiquitin ligase⁃dependent ubiquitination by small molecule compounds［J］. J Biol Chem, 2024,300（3）:105752. DOI: 10.1016/j.jbc.2024.105752.
|
| ［21］ |
Wang Y, Levin R, Martinez L, et al. POS0057 KPG⁃818, a novel cereblon modulator in patients with systemic lupus erythematosus: results of a randomize, double⁃blind, placebo⁃controlled, phase 2a study［J］. Ann Rheum Dis, 2024, 83（Supplement 1）: 329⁃330. DOI: 10.1136/annrheumdis⁃2024⁃eular.2675.
|
| ［22］ |
Furie RA, Rovin BH, Garg JP, et al. Efficacy and safety of obinutuzumab in active lupus nephritis［J］. N Engl J Med, 2025,392（15）:1471⁃1483. DOI: 10.1056/NEJMoa2410965.
|
| ［23］ |
Li W, Kolios A, Pan W, et al. Gluconolactone restores immune regulation and alleviates skin inflammation in lupus⁃prone mice and in patients with cutaneous lupus［J］. Sci Transl Med, 2025,17（786）:eadp4447. DOI: 10.1126/scitranslmed.adp4447.
|
